PARP1 and breast cancer: Patient-reported outcomes favored talazoparib, significantly improving global health status and breast symptoms [5]. An analysis of two trials that pitted single-agent PARP inhibitor therapy against standard therapy in advanced BC patients with gBRCA1/2 mutations indicated that PARP inhibitor treatment (olaparib or talazoparib) correlated with enhanced complete response rates and increased progression-free survival rates [13]. Numerous phase one and two studies have highlighted the single-agent efficacy of PARP inhibitors in metastatic BC patients with germline BRCA mutations [13, 14].